CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kang Stem Biotech Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kang Stem Biotech Co Ltd
Phone: +82 28881590p:+82 28881590 SEOUL, 06179  South Korea Ticker: 217730217730

Business Summary
Kang Stem Biotech Co., LTD is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company's product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohn’s disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Director Jong CheonNah 60
Vice President, Director Gwang WonSeo 49
Vice President Chang GyuChoi 67
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 79 (As of 3/31/2017)
Outstanding Shares: 55,937,925 (As of 12/31/2023)
Shareholders: 19,764
Stock Exchange: KDQ
Fax Number: +82 28881592


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, March 27, 2024